With this aim, the Cardio-Oncology Study Group from the Heart Failure Association (HFA) of the ESC, in collaboration with the ICOS, developed the “Baseline CV risk stratification proformas”, which is able to assess the baseline CV risk in cancer patients ongoing several classes of cancer therapies, as anthracyclines and HER2-targeted therapies are known to cause a range of CV toxicities [7] including, but not limited to, left ventricular disfunction (LVD) and HF [7]. This evidence concerns the gene ERBB2 and cancer.